Postinflammatory hyperpigmentation - Hyperpigmentation Postinflammatoirehttps://en.wikipedia.org/wiki/Hyperpigmentation
Hyperpigmentation Postinflammatoire (Postinflammatory hyperpigmentation) dia toe-pahasalaman'ny hoditra miseho amin'ny fitomboan'ny pigment ao amin'ny hoditra aorian'ny fivontosana amin'ny hoditra. hyperpigmentation postinflammatoire (postinflammatory hyperpigmentation) dia mety ho vokatry ny fiposahan'ny masoandro maharitra, ny fivontosana, na ny ratra hoditra hafa, anisan'izany ireo mifandray amin'ny akne. Ny olona manana hoditra maizina kokoa dia matetika no mora voan'ny hyperpigmentation miaraka amin'ny tara-masoandro be loatra.

☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
      References Postinflammatory Hyperpigmentation 32644576 
      NIH
      Postinflammatory hyperpigmentation (PIH) dia olana hoditra matetika mitranga aorian'ny fivontosana na ratra. Mazàna haharitra ela izy io ary ratsy kokoa amin'ny olona manana hoditra maizina (Fitzpatrick skin types III–VI) . Na dia mihatsara ho azy irery aza izy io, dia mety haka fotoana kely izany, ka matetika no ilaina ny fitsaboana mandritra ny fotoana maharitra. Ny fampifangaroana fitsaboana samihafa dia mahomby indrindra.
      Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
       Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color 20725554 
      NIH
      Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.